Last reviewed · How we verify
IC43
At a glance
| Generic name | IC43 |
|---|---|
| Also known as | IC43 Pseudomonas Aeruginosa, Pseudomonas Aeruginosa |
| Sponsor | Valneva Austria GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 (PHASE2, PHASE3)
- Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients (PHASE2)
- Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IC43 CI brief — competitive landscape report
- IC43 updates RSS · CI watch RSS
- Valneva Austria GmbH portfolio CI